Skip to main content Accessibility help
×
Home

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

  • Ferenc Martenyi (a1), Eileen B. Brown (a2), Harry Zhang (a2), Stephanie C. Koke (a2) and Apurva Prakash (a2)...

Abstract

Background

Little is known about the effect of pharmacotherapy in the prevention of post-traumatic stress disorder (PTSD) relapse.

Aims

To assess the efficacy and tolerability of fluoxetine in preventing PTSD relapse.

Method

This was a double-blind, randomised, placebo-controlled study. Following 12 weeks of acute treatment, patients who responded were re-randomised and continued in a 24-week relapse prevention phase with fluoxetine (n=69) or placebo (n=62). The primary efficacy assessment was the prevention of PTSD relapse, based on the time to relapse.

Results

Patients in the fluoxetine/fluoxetine group were less likely to relapse than patients in the fluoxetine/placebo group (P=0.027). There were no clinically significant differences in treatment-emergent adverse events between treatment groups.

Conclusions

Fluoxetine is effective and well tolerated in the prevention of PTSD relapse for up to 6 months.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
      Available formats
      ×

Copyright

Corresponding author

Apurva Prakash, Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, USA. Tel: (317) 277 8798; fax: (317) 277 9551

Footnotes

Hide All

Declaration of interest

This work was sponsored by Eli Lilly & Co.

Footnotes

References

Hide All
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Ballenger, J. C. (1999) Current treatments of the anxiety disorders in adults. Biological Psychiatry, 46, 15791594.
Blake, D. D., Weathers, F. W., Nagy, L. M., et al (1995) The development of a clinician administered PTSD scale. Journal of Traumatic Stress, 8, 7590.
Brady, K., Pearlstein, T., Asnis, G. M., et al (2000) Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA, 283, 18371844.
Breslau, N., Davis, G. C., Andreski, P., et al (1991) Traumatic events and posttraumatic stress disorder in an urban population of young adults. Archives of General Psychiatry, 48, 216222.
Connor, K. M., Sutherland, S. M., Tupler, L. A., et al (1999) Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. British Journal of Psychiatry, 175, 1722.
Davidson, J. & Colket, J.T. (1997) The eight-item treatment-outcome post-traumatic stress disorder scale: a brief measure to assess treatment outcome in post-traumatic stress disorder. International Clinical Psychopharmacology, 12, 4145.
Davidson, J., Hughes, D., Blazer, D. G., et al (1991) Post-traumatic stress disorder in the community: an epidemiological study. Psychological Medicine, 21, 713721.
Davidson, J., Book, S. W., Colket, J. T., et al (1997) Assessment of a new self-rating scale for post-traumatic stress disorder. Psychological Medicine, 27, 153160.
Davidson, J., Pearlstein, T., Londborg, P., et al (2001) Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry, 158, 19741981.
Derogatis, L. R. (1983) SCL–90–R. Administration, Scoring, and Procedures, Manual ll. Baltimore, MD: Clinical Psychometric Research.
Entsuah, A. R., Rudolph, R. L., Hackett, D., et al (1996) Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. International Clinical Psychopharmacology, ii, 137145.
First, M. B., Spitzer, R. L., Gibbon, M., et al (1997) Structured Clinical Interview for DSM–IV Axis I Disorders (SCID–I). Washington, DC: American Psychiatric Press.
Frank, E., Kupfer, D. J., Perel, J. M., et al (1990) Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 10931099.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health, Psychopharmacology Research.
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 5055.
Helzer, J. E., Robins, L. N., McEvoy, L. (1987) Posttraumatic stress disorder in the general population. Findings of the Epidemiologic Catchment Area survey. New England Journal of Medicine, 317, 16301634.
Kessler, R. C., Sonnega, A., Bromet, E., et al (1995) Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry, 52, 10481060.
Londborg, P. D., Hegel, M. T., Goldstein, S., et al (2001) Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. Journal of Clinical Psychiatry, 62, 325331.
Martenyi, F., Brown, E. B., Zhang, H., et al (2002) Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry, 63, 199206.
Michelson, D., Pollack, M., Lydiard, R. B., et al (1999) Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. British Journal of Psychiatry, 174, 213218.
Montgomery, S. A. & Asberg, M. (1979) Anew depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382389.
Montgomery, S. A., Dufour, H., Brion, S., et al (1988) The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry, 153 (suppl. 3), 6976.
Reimherr, F. W., Amsterdam, J. D., Quitkin, F. M., et al (1998) Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. American Journal of Psychiatry, 155, 12471253.
Rief, W. & Fichter, M. (1992) The Symptom Check List SCL–90–R and its ability to discriminate between dysthymia, anxiety disorders, and anorexia nervosa. Psychopathology, 25, 128138.
Rosenbaum, J. F., Fava, M., Hoog, S. L., et al (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry, 44, 7787.
Tucker, P., Zaninelli, R., Yehuda, R., et al (2001) Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo controlled, flexible dosage trial. Journal of Clinical Psychiatry, 62, 860868.

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

  • Ferenc Martenyi (a1), Eileen B. Brown (a2), Harry Zhang (a2), Stephanie C. Koke (a2) and Apurva Prakash (a2)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

  • Ferenc Martenyi (a1), Eileen B. Brown (a2), Harry Zhang (a2), Stephanie C. Koke (a2) and Apurva Prakash (a2)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *